Bisphosphonate Therapy (e.g., Pamidronate) for Osteogenesis Imperfecta
Treatment for Congenital Musculoskeletal And Limb Anomalies
Typical Dosage: Intravenous Pamidronate 0.5-1 mg/kg every 4-6 weeks; Zoledronic Acid 0.025-0.05 mg/kg every 3-6 months
Effectiveness
70%
Safety Score
65%
Clinical Trials
100
Participants
5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Dosage Range
Intravenous Pamidronate 0.5-1 mg/kg every 4-6 weeks; Zoledronic Acid 0.025-0.05 mg/kg every 3-6 months
Time to Effect
3-6 months for measurable bone density increase, longer for fracture reduction
Treatment Duration
Years to lifetime, often with treatment breaks
Evidence Quality
HIGHNumber Needed to Treat (NNT)
8(Treat 8 patients to see 1 additional successful outcome)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$5,000
Monitoring:$1,000
Side Effect Mgmt:$300
Total Annual:$6,300
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$120,000/QALY
QALYs Gained
0.4
Outcome-Based Costs
Cost per Responder
$9,000
Bisphosphonate Therapy (e.g., Pamidronate) for Osteogenesis Imperfecta Outcomes
for Congenital Musculoskeletal And Limb Anomalies
Efficacy Outcomes
Overall Effectiveness
+70%
Response Rate
+70%
Common Side Effects
Fever/flu-like symptoms (infusion related)
+30%
Nausea/vomiting
+10%
Bone/muscle pain
+5%
Hypocalcemia
+5%
Renal dysfunction (rare)
+1%
Osteonecrosis of the jaw (rare)
+0.1%
Sources:
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov